GlassScriptPhysician profile
Joseph S Park
NPI 1134387889
$69,450.48
in general payments reported to CMS, 2019-2025
25 companies · $15K in 2025
The $15K reported for 2025 was more than what 82% of Foot and Ankle Surgery providers received nationally (typical 2025 total: $1,200).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,695 · 2020: $7,696 · 2021: $6,369 · 2022: $1,247 · 2023: $22K · 2024: $8,030 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Travel and Lodging: $6,462 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,000 · Food and Beverage: $2,439 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,291.88 |
| Travel and Lodging | $6,462.49 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,000.00 |
| Food and Beverage | $2,438.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $31,239.54 | 2019-2025 | Fibergraft Aeridyan Matrix, Fibergraft Bg Morsels, Va-Lcp |
| Stryker Corporation | $8,479.15 | 2019-2025 | System 9 Cd Nxt, Ezout, Infinity Adaptis |
| Depuy Synthes Products, INC. | $7,140.00 | 2023 | Va-Lcp |
| Synthes USA Products LLC | $6,957.56 | 2023 | Va-Lcp, Expert Nail, Na |
| Trimed, INC. | $4,062.60 | 2025 | |
| Depuy Synthes Sales INC. | $2,668.19 | 2019-2025 | Va-Lcp, Hammerlock, Na |
| Arthrex, INC. | $2,440.40 | 2019-2023 | Distal Extremities Implants Soft Tissue Ib Ligament Augmentation |
| Integra Lifesciences Corporation | $1,899.68 | 2019-2020 | |
| Treace Medical Concepts, INC. | $1,671.50 | 2025 | |
| Rivanna Medical, INC | $875.00 | 2022-2023 | Accuro |
| Fortis Surgical, LLC | $580.04 | 2021-2023 | |
| Lifenet Health | $500.00 | 2024 | Pliafx Flo |
| Linvatec Corporation | $314.08 | 2019-2023 | Quantum |
| Ibsa Pharma INC. | $125.00 | 2021 | |
| Wright Medical Technology, INC. | $104.11 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novastep INC. | $86.61 | 2022 | |
| Peter Brasseler Holdings, LLC | $75.82 | 2025 | |
| Paragon 28, INC. | $53.36 | 2019-2023 | Portfolio |
| Biocomposites INC | $43.32 | 2021 | |
| Zimmer Biomet Holdings, INC. | $40.69 | 2020 | |
| In2bones USA, LLC | $27.74 | 2019 | |
| Bioventus LLC | $21.79 | 2019 | |
| Brainlab, INC. | $17.63 | 2021-2022 | |
| Sanofi Pasteur INC. | $13.72 | 2020 | |
| Smith+Nephew, INC. | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.